Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol-Myers Squibb Plans To Make India Its Global Pharma Innovation Hub

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD, India - Bristol-Myers Squibb may not be as aggressive as its larger multinational competitors in playing the generics or the branded generics card, but the company best known for blockbusters like Abilify (aripiprazole) and Plavix (clopidogrel) has brought under sharp focus partnership-based research for developing innovative drugs in India

You may also be interested in...



BMS, Biocon Team Up To Rekindle Oral Insulin Hopes

After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”

BMS, Biocon Team Up To Rekindle Oral Insulin Hopes

After faltering last year with clinical development of its oral insulin, Biocon’s long hunt for a partner ends with Bristol-Myers Squibb, which signed a carefully worded “exclusive option agreement.”

Biocon Chairman Kiran Mazumdar-Shaw On Hopes For An Oral Diabetes Drug, And Risks And Rewards Of Innovation: An Interview with PharmAsia News

Biocon Chairman And Managing Director Kiran Mazumdar-Shaw shares her business development strategy and newest pipeline developments with PharmAsia News in an exclusive interview.

Related Content

Latest News
UsernamePublicRestriction

Register

SC075998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel